Current research studies

Current research studies

We’re currently taking part in more than 50 different research projects, all aiming to improve health outcomes for our communities.

Take a look at the areas we’re working in, and find out how you can be a part of research here with us in Bolton.

AKIS registry study

The aim of the AKIS registry study is to assess the use and safety of an intravenous (IV) bolus formulation of Akis® in hospital settings.

Akis® is a non-steroidal anti-inflammatory drug (NSAID) and is used in the prevention and treatment of pain following an operation.

Principal Investigator: Pete Sandbach

REMoDL-A

REMoDL-A is an open label randomised phase II trial examining the efficacy of two combined cancer treatments, R-CHOP and acalabrutinib chemoimmunotherapy, in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) compared to R-CHOP alone.

Principal Investigator: Chetan Patalapa

ATNEC

ATNEC is a phase III, open, randomised, multicentre trial comparing standard axillary treatment (either, axillary lymph node dissection [ALND] or axillary radiotherapy [ART]) with no axillary treatment post-surgery, in early stage breast cancer patients.

Principal Investigator: Ricardo Pardo Garcia

POLARIS

POLARIS is a prospective, multicenter, noninterventional study assessing palbociclib, a type of targeted cancer drug, in hormone receptor-positive advanced breast cancer.

Principal Investigator: Ian Farrell

OPTIMA

OPTIMA is a patient driven clinical study for people with hormone sensitive early breast cancer. The study aims to improve the way decisions are made about who is offered chemotherapy following surgery.

Principal Investigator: Catherine Blake

SMALL

The SMALL study is a phase 3 clinical trial designed to test if radiotherapy-guided surgical removal could be more effective as a treatment option for women with early-stage breast cancer, which has been detected through the NHS screening programme.

Principal Investigator: Clare Garnsey

TRIAGE-HF_V1.0

TRIAGE-HF_V1.0 is an evaluation of the clinical workload burden associated with implementing a new care pathway that remotely monitors and manages heart-failure, Triage-HF Plus, and the related clinical workload burden before using this new pathway.

Principal Investigator: Karen Lipscomb

SPIROMAC

The SPIROMAC study will help to understand whether spirometry, a simple breathing test, to help guide preventer treatment can reduce the number of asthma attacks in children.

Principal Investigator: Susan Glass

MOSAICC

MOSAICC is evaluating the clinical and cost-effectiveness of Sodium Bicarbonate administration for critically ill patients with Acute Kidney Injury and metabolic acidosis.

Principal Investigator: Madhu Balasubramaniam

SIGNET

SIGNET is a randomised controlled trial in organ donation, evaluating the benefits of a single dose of Simvastatin, a safe and commonly used drug, given to organ donors and whether it might limit the damage sustained by a donor heart before it is transplanted.

Principal Investigator: Hannah Durrant

UK-ROX

UK-ROX is a large-scale, clinical trial to find out whether using a lower oxygen target (conservative oxygen therapy) to guide oxygen treatment might lead to better outcomes for patients when compared with the approach currently used in the NHS (usual oxygen therapy) when treating ICU patients on an ventilaton.

Principal Investigator: Madhu Balasubramaniam

VITDALIZE UK

The VITDALIZE UK Trial forms part of a large international randomised controlled trial to determine if treatment with a high dose of vitamin D improves patient outcomes and is cost-effective in comparison to the placebo in severely vitamin D deficient critically ill patients admitted to an intensive care unit.

Principal Investigator: Gareth Hughes

GenOMICC

GenOMICC is a global study that aims to discover specific genes that control the processes that lead to life-threatening illness, such as sepsis and Flu, to improve understanding and the ability to design effective treatments.

Principal Investigator: Gareth Hughes

ADAPT-SEPSIS

The aim of the ADAPT-SEPSIS study is to find out whether the duration of antibiotic treatment given to patients with sepsis can be safely reduced following the close daily monitoring of these biomarkers.

Principal Investigator: Madhu Balasubramaniam

ADDRESS-2 DRN 552

​​​​​DRN 552 is a database collecting data from newly diagnosed patients with Type 1 diabetes, which may lead to progression onto other studi

Principal Investigator: John McKinnon

STARFISH Trial

The STARFISH trial will find out the best method of giving steroid treatment for people with idiopathic sudden sensorineural hearing loss.

Principal Investigator: Vikas Malik

NAZA

NAZA is a cohort study in patients with moderate to severely active Crohns Disease (CD) and Ulcerative Colitis (UC) who are switching to new targeted biologic therapy. It is hoped the study will help improve our understanding of Inflammatory Bowel Diseases (IBD) and help us to develop better ways of treating the condition and predicting the course of the disease and how patients may respond to different treatments.

Principal Investigator: Ben Crooks

GONDOMAR

GONDOMAR (GOals, Needs and Determinants Of Multimodal therapy in periAnal cRohn’s fistula) is a study that is recruiting thousands of patients with perianal fistulas, a common complication of Crohn’s Disease. GONDOMAR will be developed into a research platform where different hospitals and clinics in the UK can share their learning and knowledge around perianal fistulas and identify best practice to improve outcomes for patients.

Principal Investigator: Ben Crooks

COLO-COHORT

COLO-COHORT (Colorectal Cancer Cohort Study) aims to develop a “risk stratification tool” to help identify which patients are at highest risk of having adenomas or bowel cancer.

Principal Investigator: Salil Singh

BOBO

BOBO is measuring the quality of life in care pathways for Barrett’s Oesophagus, a condition where some of the cells in your oesophagus grow abnormally and can slightly increase chances of getting oesophageal cancer.

Principal Investigator: Mark Murgatroyd

RECOVERY

RECOVERY is an international clinical trial identifying treatments that may be beneficial for people hospitalised with pneumonia. The trial started in the UK in 2020 testing treatments for people admitted to hospital with COVID-19 pneumonia, identifying four life-saving treatments. It’s now expanded to test other types of pneumonia.

Principal Investigator: Madhu Balasubramaniam

REDUCe2

REDUCe2 will compare insertion of a palliative tunnelled long-term abdominal drain (LTAD) (Group 1 intervention) to standard of care (Group 2 intervention) large volume paracentesis (LVP) in the management of refractory ascites, a condition where fluid collects in spaces within the abdomen.

Principal Investigator: Mahesh Bhalme

BOPPP

BOPPP will examine the efficacy using the non-selective beta-blocker, Carvedilol, as primary prophylaxis to prevent variceal haemorrhage in patients with cirrhosis, scarring of the liver, and small oesophageal varices.

Principal Investigator: Mahesh Bhalme

The UK-PBC Nested Cohort Study (version 1)

The UK-PBC Nested Cohort Study is aimed at finding out why treatment with ursodeoxycholic acid (UDCA) is highly effective in some people with primary biliary cholangitis (PBC), a chronic liver disease that causes scarring of the liver, but less effective in others.

Principal Investigator: Mahesh Bhalme

CHAPTER

CHAPTER is a study to optimise the care of women following childbirth related perineal trauma (CRPT), bringing together women, the public, midwives, doctors and academics to improve the care for women with CRPT.

Principal Investigator: Emma Tanton

STOPPIT-3

STOPPIT-3 aims to find out if medicines called antenatal corticosteroids (ACS) given to women with a twin pregnancy prior to a planned birth of twins after 35 weeks of pregnancy reduces breathing difficulties in the twin babies.

Principal Investigator: Bim Williams

SNAP 3

The SNAP 3 study provides NHS stop smoking support, including Nicotine Replacement Therapy (NRT), such as nicotine patches, used in new and effective ways.

Principal Investigator: Emma Tanton

iGBS3

The iGBS3 trial is collecting comprehensive information about the amount of antibody that protects babies from GBS infection, the most common cause of life-threatening infection in newborn babies in the UK, so that the researchers can establish what the components of a GBS vaccine need to be to reduce GBS infection in babies.

Principal Investigator: Priti Wuppalapatti

The Tommy’s National Rainbow Clinic Study

The Tommy’s National Rainbow Clinic Study is accessing the impact of the Tommy’s Rainbow Clinic, a specialist service for parents who have suffered a stillbirth or neonatal death that provides the best possible care to help and support them through a subsequent pregnancy.

Principal Investigator: Khalida Javaid

GBS3

This GBS3 trial is looking at whether testing pregnant women for Group B Streptococcus, a common bacteria that normally causes no harm, reduces the risk of infection in newborn babies compared to the current strategy in place in the UK. The current strategy in the UK is to offer antibiotics during labour to women who are considered at raised risk of their baby developing a group B Strep infection.

Principal Investigator: Priti Wuppalapatti

TTTS registry

The Twin to Twin Transfusion Syndrome (TTTS) registry aims to collect data on the disease, diagnosis and treatment to better identify the most effective treatments for this condition.

Principal Investigator: Ilze Zommere

OBS UK

The Obstetric Bleeding Study UK (OBS UK) is looking at whether a new care bundle which helps manage heavy bleeding during and after childbirth could improve outcomes and then advise the new UK standard guidance.

Principal Investigator: Andrew McTavish

MiNESS – The Midlands and North of England Stillbirth Study

MiNESS is the fourth and largest study to compare the sleeping habits of women in late pregnancy (after 28 weeks) who had a stillborn baby with women at the same stage in pregnancy who went on to have a healthy baby.

Principal Investigator: Emma Tanton

SurfON

SurfON is a multicentre, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress.

Principal Investigator: Archana Mishra

neoAMRO

neoAMRO is aiming to identify the infections leading to death in babies on neonatal units, define the clinical characteristics of babies dying from infections, and describe the management with a specific focus on babies antimicrobial treatment and the antimicrobial resistance profiles.

REPPORT

The REPPORT trial is looking to compare a physiotherapy intervention (PKT: Personalised Knee Therapy) versus surgery for recurrent dislocations and instability of the knee cap, which can be a profoundly disabling condition.

Principal Investigator: James Childs

IMID BioResource

The IMID BioResource is a recallable resource of participants with Immune-Mediated Inflammatory Diseases (IMIDs), a wide group of common health conditions which cause inflammation in the body, including rheumatoid arthritis, systemic lupus erythematosus and psoriasis with cross cutting co-morbidities.

Principal Investigator: Anindita Paul

The ORION Trial

The aim of the ORION trial is to assess whether radiofrequency ablation (RFA) is as efficacious as existing methods of treating haemorrhoids and if it is also superior in terms of pain and recurrence.

Principal Investigator: Dave Smith

The Sunflower Study

The Sunflower Study is a randomised controlled trial to establish the clinical and cost effectiveness of expectant management versus pre operative imaging with Magnetic Resonance Cholangiopancreatography (MRCP) in patients with symptomatic gallstones undergoing laparoscopic cholecystectomy at low or moderate risk of common bile duct stones.

Principal Investigator: Bohdan Smajer

To find out how to get involved or for more information on research opportunities at Bolton NHS FT, please get in touch with the Research Team on 01204 390445 or email research@boltonft.nhs.uk.

Skip to content